kabutan

HEALIOS K.K.(4593) Summary

4593
TSE Growth
HEALIOS K.K.
410
JPY
-3
(-0.73%)
Mar 13, 3:30 pm JST
2.57
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
405
Mar 13, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
11.3
Yield
ー%
Margin Trading Ratio
18.69
Stock Price
Mar 13, 2026
Opening Mar 13, 9:03 am
400 JPY 2.51 USD
Previous Close Mar 12
413 JPY 2.59 USD
High Mar 13, 12:53 pm
411 JPY 2.57 USD
Low Mar 13, 9:04 am
399 JPY 2.50 USD
Volume
2,209,800
Trading Value
0.89B JPY 5.60M USD
VWAP
404.19 JPY 2.54 USD
Minimum Trading Value
41,000 JPY 257 USD
Market Cap
0.06T JPY 0.35B USD
Number of Trades
1,303
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
2,938
1-Year High Jul 17, 2025
31,879
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 1,853,000 10,385,700 5.60
Feb 27, 2026 1,863,300 10,409,200 5.59
Feb 20, 2026 1,775,600 11,813,700 6.65
Feb 13, 2026 1,700,400 11,983,700 7.05
Feb 6, 2026 1,683,400 12,132,900 7.21
Company Profile
HEALIOS K.K. develops treatments for intractable diseases using iPS cells. The company collaborates with Sumitomo Pharma and has a business alliance with Nikon.
Sector
Pharmaceuticals
HEALIOS K.K. conducts research and development of regenerative medicine products utilizing iPS cell technology. In the field of somatic stem cell regenerative medicine, the company is advancing the development of HLCM051 for acute cerebral infarction and ARDS (Acute Respiratory Distress Syndrome). In the iPSC regenerative medicine field, which involves transplanting cells with functions similar to the human body created by differentiating iPS cells, HEALIOS K.K. is developing a next-generation platform to create Universal Donor Cells (UDC) with reduced risk of immune rejection. The company's pipeline includes research and development in cancer immunotherapy, age-related macular degeneration treatment, and liver disease treatment. Through joint development with Sumitomo Pharma and collaborations with domestic and international research institutions, HEALIOS K.K. aims to realize new treatments for intractable diseases.